Roche says Japan approves new formulation of arthritis drug
ZURICH (Reuters) - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra.
Japanese regulators have approved a subcutaneous formulation of Actemra which shortens the delivery time of the drug compared to an intravenous formulation and can be administered at home.
Actemra was first launched with intravenous formulation in Japan for Castleman's disease and was later approved for rheumatoid arthritis.
Roche has also submitted the subcutaneous formulation for approval in the United States and Europe, where Actemra is approved for use in rheumatoid arthritis patients who are either intolerant to or have failed to respond to other medicines to treat inflammation.
(Reporting by Caroline Copley)
- Air strike kills 15 civilians in Yemen by mistake: officials
- Pope attacks mega-salaries and wealth gap in peace message
- North Korea says Jang Song Thaek, uncle of leader Kim Jong Un, executed
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
Thousands line up to say goodbye to Nelson Mandela, whose body is lying in state in Pretoria. Slideshow